ENDP - Eagle Pharmaceuticals gets 180 days marketing exclusivity for Endo's Vasostrict generic

Eagle Pharmaceuticals (EGRX -0.2%) received 180 days of marketing exclusivity from the the U.S. Food and Drug Administration for its recently approved generic version of Endo International's (ENDP -1.5%) Vasostrict (vasopressin). Earlier in December, Eagle noted that that Par Pharmaceutical, owned by Endo, had unilaterally withdrawn its bid to block the launch of generic alternative to Vasostrict through a court ruling. Eagle added that in August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product did not infringe any of the patents Par asserted against the company. Eagle's President and CEO Scott Tarriff said, "2022 will be an exciting period for us with our upcoming launch of vasopressin, as well as our launch of PEMFEXY, beginning on February 1, 2022.”

For further details see:

Eagle Pharmaceuticals gets 180 days marketing exclusivity for Endo’s Vasostrict generic